You are here: Industry Insights > RSV

News List

Nirsevimab shows promise for long-term RSV protection pharmatimes
July 31, 2020
AstraZeneca and Sanofi's nirsevimab has shown a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial
AZ sells rights to RSV virus drug to Sobi for $1.5bn pharmaphorum
December 11, 2018
AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payments.
AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn pharmatimes
November 14, 2018
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory syncytial virus (RSV)...
AstraZeneca divests US rights to Synagis pharmatimes
November 14, 2018
Swedish Orphan Biovitrum AB has entered into an agreement to buy US rights to AstraZeneca’s Synagis, licensed for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV).
Johnson & Johnson steps up vaccines R&D—and prepares for launches—with €72M plant fiercepharma
November 09, 2018
Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing has to measure up. The small plant acquired in its Crucell purchase just won't support...
Antigen study provides a new approach to vaccine development for RSV europeanpharmaceuticalreview
March 14, 2018
Medical researchers point to a promising route for designing an effective vaccine for the respiratory syncytial virus…
Virus-like particle vaccine protects against RSV vaccine-enhanced respiratory disease europeanpharmaceuticalreview
November 27, 2017
Researchers have discovered that a virus-like particle vaccine can prime the body’s immune response and prevent the severe respiratory diseases…
RSV vaccine player Codagenix snags $3M in public and private investment fiercepharma
October 13, 2017
Add a new contender to the list of companies aspiring to develop an effective respiratory syncytial virus (RSV) vaccine and nab a share of a potential multibillion-dollar market: Codagenix.
Regeneron drops RSV therapy on trial failure pharmatimes
August 16, 2017
Regeneron Pharmaceuticals is pulling the plug on an experimental therapy in development for preventing respiratory syncytial virus (RSV) infection in infants, after a disappointing performance in a late-stage trial
Regeneron abandons respiratory syncytial virus therapy after late-stage failure pharmafile
August 16, 2017
Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the company has decided to scrap its further development

Previous page 1 2 3 4 Next page